drugset / Trial / NCT05921292

Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

NCT05921292

Phase 0 Completed 111 enrolled Omeza, LLC
NaSingle-groupOpen-labelOther

Summary

The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is: \- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period? Patients will be treated with: * OCM™ Wound Matrix * Omeza combination therapy * Standard of Care

Timeline

Start
2022-07-11
Primary completion
2024-01-22
Completion
2024-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 2 ml Topical
Subject Omeza skin protectant Unknown 2 ml Topical
Subject Omeza® Complete Matrix Unknown 1.6 g Topical

Indications